Vanguard Group Inc. Raises Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Vanguard Group Inc. raised its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,815,596 shares of the company’s stock after purchasing an additional 48,203 shares during the period. Vanguard Group Inc. owned 5.85% of Amphastar Pharmaceuticals worth $174,145,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $28,000. Principal Securities Inc. purchased a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth $34,000. Quadrant Capital Group LLC boosted its position in shares of Amphastar Pharmaceuticals by 27.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after acquiring an additional 223 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Amphastar Pharmaceuticals by 115.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock valued at $150,000 after purchasing an additional 1,300 shares during the period. Finally, Leeward Financial Partners LLC acquired a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $217,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Insiders Place Their Bets

In related news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the transaction, the director now owns 78,409 shares in the company, valued at $3,246,132.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 3,596 shares of the stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $40.93, for a total value of $147,184.28. Following the sale, the chief financial officer now owns 94,103 shares of the company’s stock, valued at approximately $3,851,635.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the transaction, the director now owns 78,409 shares of the company’s stock, valued at approximately $3,246,132.60. The disclosure for this sale can be found here. Insiders have sold 7,596 shares of company stock worth $313,544 over the last three months. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Up 2.6 %

Amphastar Pharmaceuticals stock opened at $38.56 on Thursday. The company has a market capitalization of $1.89 billion, a PE ratio of 13.34, a price-to-earnings-growth ratio of 0.82 and a beta of 0.80. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.72 and a current ratio of 2.18. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $37.30 and a fifty-two week high of $67.66. The firm has a 50 day moving average price of $41.47 and a 200 day moving average price of $47.42.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, May 8th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.20. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. The business had revenue of $171.84 million during the quarter, compared to analysts’ expectations of $171.13 million. Research analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.6 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 13th. Piper Sandler reissued an “overweight” rating and set a $71.00 target price on shares of Amphastar Pharmaceuticals in a research note on Thursday, June 27th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, May 22nd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $66.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.